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• Two databases, Scopus and PubMed, were searched 
using 21 search terms generated from three main 
concepts: “traumatic brain injury” (n=3), “neurobehavioral 
function” (n=6), and “outcomes” (n=12). 
• Study inclusion criteria: 
- Published within the past 5 years
- Involving adult humans (>18 years old)
- Relevant to severe TBI
- Relevant to DOC
• The initial search identified 229 articles were identified 
After the removal of duplicates, 211 articles were 
retained and reviewed for inclusion. 
• 58  met the inclusion criteria. These articles were 
grouped thematically based on content related to 
assessment of NBF and recovery of consciousness. 
• Four themes were identified: “Predicting Outcomes”, 
“Non-Pharmacology Treatment”, “Pharmacotherapy”, 
and “Neural Pathways”.
• Clinical Outcomes were identified within each article and 
grouped as occurrences related to “clinical outcome 
assessments”, biometrics and biomarkers”, 
“neuroimaging and neurophysiology”, and “other”.
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Background
• This scoping review aims to report the findings of current 
literature examining the assessment of neurobehavioral 
function and recovery along the continuum of disorders 
of consciousness (DOC) from coma to full 
consciousness.
• This study is designed to capture the range of constructs 
researchers have used to measure NBF during recovery 
of consciousness
• The research question for this review was:
“What constructs are most frequently used to assess 
neurobehavioral function in adults recovering 
consciousness after severe TBI?”
• Approximately 10% of the 1.7 million traumatic brain 
injuries (TBI) that occur each year in the US are 
considered severe and result in significant disability 
(CDC, 2016)
• As of 2015, there is no approved drug or device to treat 
TBI. 
• A challenge in demonstrating the effectiveness of drugs 
and devices to treat TBI is the lack of sufficiently precise 
outcome assessments that are approved as federally 
qualified endpoints. 
- The Glasgow Coma Scale  (GCS) and Glasgow 
Outcomes Scale (GOS) are the most commonly-used 
measures of neurobehavioral function (NBF) in TBI 
clinical trials.
• Clinical Outcome Assessments (COAs) are “reported” 
assessments influenced by human choices, judgment, or 
motivation and may provide direct of indirect evidence to 
treatment benefit. 
• Four types of COAs: 
- Patient reported outcome (PRO)
- Clinician-reported outcome (ClinRO) measures
- Observer-reported outcome (ObsRO) measure
- Performance outcome (PerfO) measures
• FDA Federally Qualified Endpoint Measures: Roadmap 
to patient-focused outcome measurement includes:
- Understanding the disease
- Conceptualizing treatment benefit
- Selecting/Developing outcome measures
• TBI initiatives are attempting to advance the state of the 
science by identifying and validating clinical outcome 
assessments as qualified endpoints.
- TED Initiative: https://tbiendpoints.ucsf.edu/
• Neurobehavioral rating scales detect behavioral signs of 
consciousness, while biomarkers are perceived as being 
more precise measures of the disease not impacted by 
human factors
• COAs and biomarkers have potential to measure 
treatment effect
Study Aims Analytic Framework
Current Literature Focuses on Predicting Outcomes
• The most frequently occurring theme was Predicting 
Outcomes, followed by Non-Pharmacotherapy treatment.  
• Studies primarily focused on predicting outcomes of 
patients with TBI. There were many fewer studies 
describing effective treatments for these patients.
• The focus on predicting outcomes appears to be off 
target when current classification of TBI severity and type 
is blunt and treatments for severe TBI are limited. 
Diversity of Outcome Measures Dilutes Evidence 
Base
• This study found a remarkable range in the diversity of 
reported COAs, biomarkers, neuroimaging and 
neurophysiology techniques. 
- This creates challenges in comparing results across 
studies and consequently limits the translation of 
knowledge into practice.
• 50 different COAs were identified but only 3 were 
reported in more than 25% of the articles (GCS, 
GOS/GOSE, CRS/CRS-R). 
- The GCS and GOSE are relatively blunt measures of 
NBF recovery and the CRS-R has no published 
sensitivity to change indices.
Connecting Mechanisms of Recovery to Treatment 
and Outcomes Measurement
• Only a few articles were found related to “neural 
pathways”. 
• Understanding the mechanisms of pathology in brain 
injury and neuroplasticity will likely play a critical role in 
more precise diagnosis and more targeted with treatment 
for these patients.
• There appears to be a gap in the literature regarding 
precision in severe TBI diagnoses and and linking this to 
brain pathology in order to design more appropriate and 
effective treatments.
Future Directions
• This study identified a wide range of COAs measuring 
NBF. The extent to which these assessments address the 
same content domains and if some domains are poorly 
addressed remains unknown.
• Treatments for patients with severe TBI could be 
developed in parallel with studies aimed at better 
understanding the brain’s pathways and response to TBI. 
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Search timeframe was limited to studies within the last 5 
years. 
Articles in the scoping review are not read to analyze bias 
or the quality of the study.





Figure 1. Search criteria for scoping review adapted using Health 
Evidence™  (2009)
Results
Figure 2. Frequency of Themes By Article
Most Commonly Occurring Themes Were Predicting 









Amantadine Progesterone Baclofen Rosuvastatin Levetiracetam
Pharmacotherapy Articles Most Often Reported on 
Amantadine, Progesterone, and Baclofen
Figure 3. Frequency of Articles Reporting on Drugs used as 
Pharmacotherapy for Severe TBI
Predicting Outcomes
• Most common constructs included: 
- Role of genotypes & biomarkers
- Neuro-imaging & neurophysiology
- Observed behaviors in response to sensory input 
(e.g. head turning and visual fixation)
Non-Pharmacotherapy Treatment
• Most common constructs included:
- Electrical stimulation, 
- Coma stimulation, 
- Hypothermia, 
- Familiar voice auditory stimulation, and 
- Interdisciplinary care models.
Neural Pathways
• Most common constructs included relationship between 
“neural pathways” and recovery of consciousness.
- Auditory network more functionally connected in 
patients in a minimally conscious state
- Goal directed activity may be inhibited due to inability 
to coordinate precuneus fiber tracts
Pharmacotherapy




• A scoping review examines the extent and nature of the 
research, identifies gaps in the literature, and may 
establish the significance of commencing a full systematic 
review (Levac, Colquhoun, & O’Brien, 2010)
• The scoping review methodological framework for this study 
followed that of Arksey & O’Malley (2005): 1) identify the 
research question, 2) identify relevant studies, select 
studies, 3) chart the data, 4) collate, summarize and report 
results.
• Thematic analysis focuses on different topics within a 
subject and their inter-relationships by interpreting the 
articles.


































• 162 incidences of COAs were reported in 58 articles
- The majority of incidences of COAs reported were 
ClinROs (n=138)
• The most frequently reported ClinROs were: 
- Glasgow Coma Scale: 29 articles
- Coma Recovery Scale-Revised: 21 articles
- Glasgow Outcome Scale or GOS-Extended: 17 
articles
• 50 different COAs were identified
• No ObsROs or PerfROs were found in any of the articles
Neuro-Imaging and Neurophysiology
• A total of 11 different techniques were identified
- The most commonly reported included: CT, MRI, and 
EEG
- Others included: DTI, IMSPECT, and PET
Biometrics and Biomarkers
• A total of 8 biomarkers were reported in 10 articles
- APOE e4 genotype was associated with increased 
risk of worse long term functional outcome after TBI
- A10398 allele associated with slower recovery time
- Other biomarkers included: H-FABP, MAP-2, BDNF, 
TNF, and ChE.
Other
• Other commonly identified outcomes included:




















Other Biometrics & Biomarkers
Most Commonly Identified Outcome Measures Were
Clinical Outcome Assessments
















Most Frequently Reported Clinical Outcome Assessments 
Were Clinician-Reported Outcomes
Figure 5. Frequency of the types of COAs found in the articles.





Indirect Measures                      Direct Measures
Image Adapted from Burke (2011)
